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Battery-free, fully implantable optofluidic cuff system 
for wireless optogenetic and pharmacological 
neuromodulation of peripheral nerves
Yi Zhang1,2*, Aaron D. Mickle3,4*, Philipp Gutruf5,2*, Lisa A. McIlvried3,4*, Hexia Guo2, Yixin Wu2, 
Judith P. Golden3,4, Yeguang Xue6,7, Jose G. Grajales-Reyes3,4, Xueju Wang8, Siddharth Krishnan2, 
Yiwen Xie2, Dongsheng Peng2,9, Chun-Ju Su2, Fengyi Zhang10, Jonathan T. Reeder2,  
Sherri K. Vogt3,4, Yonggang Huang2,6,7, John A. Rogers2,11,12,13,14,15†, Robert W. Gereau IV3,4,16†
Studies of the peripheral nervous system rely on controlled manipulation of neuronal function with pharmacologic 
and/or optogenetic techniques. Traditional hardware for these purposes can cause notable damage to fragile 
nerve tissues, create irritation at the biotic/abiotic interface, and alter the natural behaviors of animals. Here, we 
present a wireless, battery-free device that integrates a microscale inorganic light-emitting diode and an ultralow- 
power microfluidic system with an electrochemical pumping mechanism in a soft platform that can be mounted 
onto target peripheral nerves for programmed delivery of light and/or pharmacological agents in freely moving 
animals. Biocompliant designs lead to minimal effects on overall nerve health and function, even with chronic use 
in vivo. The small size and light weight construction allow for deployment as fully implantable devices in mice. 
These features create opportunities for studies of the peripheral nervous system outside of the scope of those 
possible with existing technologies.
INTRODUCTION
Pharmacology and optogenetics represent two distinct, and often 
complementary, approaches that are widely used in neuroscience 
research (1–10). Optogenetics allows for light-dependent activation 
or inhibition of function in genetically defined neuronal populations, 
with the ability to manipulate and study discrete neuronal circuits 
(1, 8, 11). Pharmacology can target specific cellular process, from 
cell surface receptor or ion channel function to intracellular signaling, 
without the need for genetic modifications. Protocols for interrogating 
neural circuits while measuring subtle animal behaviors with either 
of these methods are, however, often restricted by limitations of the 
supporting hardware technologies, especially for studies of freely 
moving small animals. For example, traditional optogenetic assays 
rely on fiber-optic cables coupled to external light sources (12). In 
vivo pharmacological studies require tubing that connects to separate 
reservoirs and micropumps, or they require syringe injections while the 
animals are physically restrained and/or anesthetized. These approaches 
can (i) damage sensitive tissues during injection or implantation, 
(ii) cause persistent irritation at the biotic/abiotic interface due 
to mechanical interaction between the delivery hardware and the 
surrounding soft, moving tissues, and (iii) introduce physical 
constraints on the natural movements of the animals, thereby 
affecting or preventing free motions and increasing stress and anxiety 
(13–16). These technical shortcomings limit options in experimental 
design and can confound the interpretation of experimental results.
Efforts to address these limitations have advanced in optogenetics, 
where a variety of systems based on microscale light-emitting diodes 
and wireless powering strategies are now available (17–20). Devices 
for the peripheral nervous system (PNS) can broadly illuminate 
sensory neuron peripheral terminals in large structures (17, 18, 21) 
or the central terminals projecting into the spinal cord (17, 18, 20). 
Challenges persist, however, in noninvasive methods for (i) securing 
the devices to the PNS or adjacent anatomical structures and (ii) 
enabling sufficient mechanical compliance to accommodate the 
movements that occur in awake behaving animals. Difficulties in 
establishing pharmacological interfaces with peripheral nerves are 
even more pronounced, particularly in small animals. Currently 
available methods for drug delivery via catheters or syringes do not 
address these confounds. Recently reported battery- powered, wire-
less, head-mounted optofluidic platforms anchor to rigid parts of 
the anatomy such as the skull for studies of the brain (10). Certain 
features, however, prevent their use for interfacing with the PNS: 
(i) Thermal-mechanical actuation of the microfluidic pumps demands 
substantial power, thereby requiring batteries with sizes and weights 
(0.66 g) that are nonideal for the full implantation in mice; (ii) the 
heat generated during the operation of these micropumps could 
degrade temperature-sensitive pharmacological agents, thereby re-
stricting the range of uses; (iii) functional lifetime depends on the 
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battery capacity, thereby preventing chronic, longitudinal studies; 
and (iv) the absence of a means to refill the microfluidic chambers 
prevents the reuse of the systems. These shortcomings motivate the 
design of a new microfluidic fluid delivery system for use in chronic 
in vivo studies of the PNS.
Here, we present a wireless, battery-free, fully implantable device 
with the capability for programmed delivery of localized optical and/or 
pharmacological stimuli, designed to eliminate key disadvantages 
of previously reported approaches. The device includes an ultralow- 
power, miniaturized electrochemical micropump system to drive fluid 
delivery via microfluidic channels incorporated in a soft optofluidic 
cuff that surrounds a targeted nerve. Operation of these devices 
occurs in freely moving animals, without the need for handling or 
physical manipulation. We show that these devices remain in position 
without signs of damage to the nerves 10 weeks after implantation. In 
vivo studies demonstrate the capabilities to positively (optogenetic 
stimulation) and negatively (bupivacaine delivery) modulate nocicep-
tion in freely behaving mice. The ability to target specific peripheral 
neuron populations in awake behaving animals, over extended periods 
of time, is of broad potential interest to the neuroscience community.
RESULTS
Design of the wireless, battery-free optofluidic cuff system
The device consists of six subsystems: (i) a low-modulus (~3 MPa), 
elastomeric cuff that supports chronic interfacing with peripheral 
nerves; (ii) a thin microfluidic channel structure (four channels 
each with cross-sectional areas of 60 m by 60 m; total thickness, 
~200 m) that terminates at the cuff for targeted delivery of 
pharmacological agents (i.e., drugs) at the cuff-nerve interface; (iii) 
a high-efficiency, microscale inorganic light-emitting diode (-ILED; 
270 m by 220 m by 50 m) that also resides in the cuff for delivering 
light at the target location; (iv) a base station (radius, 5 mm; thickness, 
~4 mm) that contains fluid reservoirs, programmable pumping 
microsystems, and hardware for wireless power harvesting, control, 
and management; (v) a mechanically compliant, serpentine electronic 
interconnect joining the -ILED to the base station (Fig. 1, A to E); 
and (vi) a collection of external hardware and software systems for 
independent, wireless control over the -ILED and microfluidics 
(fig. S1). In the device described here, four miniaturized electro-
chemical micropumps, selected because of their low power consump-
tion and negligible heat generation, couple to a corresponding set of 
reservoirs to initiate the flow of drugs at user-selected times (Fig. 1E). 
The small size and light weight (~0.3 g) of this integrated system 
allow for complete implantation, even into small animals such as 
mice. Fully wireless operation eliminates the need to directly handle, 
anesthetize, or inject the animals after the initial implantation, thereby 
avoiding stress and/or pain that could otherwise lead to experimental 
artifacts in behavioral testing.
Wireless energy harvesting and power management occur through 
an electronics module that uses resonant near-field coupling and 
custom control software (22). Here, power transfer follows from 
magnetic inductive coupling at a frequency of 13.56 MHz, matched 
to near-field communication (NFC) interfaces found in consumer 
electronics and also in recently reported devices for optogenetics 
(19–21). Operation is compatible with many environments, including 
cages with metal plates or meshes and arenas with water pools or 
mazes. Further, the system can operate over large areas (thousands 
of square centimeters) (19). A thin, flexible printed circuit board 
serves as a substrate for a radio frequency (RF) coil antenna, a set of 
capacitors, a rectifier, and a microcontroller (Fig. 1, E and F, and fig. 
S1, A and B). The rectifier includes a matching capacitor (82 pF) to 
support resonant operation at 13.56 MHz and two Schottky diodes 
to rectify the received RF signals. Programmable control over a 
separate micropump for each reservoir occurs through a micro-
controller that activates by amplitude shift keying, in a manner 
compatible with the control hardware (Fig. 1F) (23). The complete 
system includes a software interface, a multicomponent power 
distribution control box, an antenna tuner, and a customizable 
antenna (fig. S1C).
Ultralow-power, miniaturized electrochemical micropumps
The ultralow-power, miniaturized electrochemical micropumps 
represent key components of the system. In general, micropump 
actuation can be achieved with osmotic pressure, fluorocarbon 
propellants, electromagnetic forces, piezoelectric transducers, 
electrostatic impellers, thermopneumatic effects, and electrochemical 
methods (24–27). The electrochemical method, as implemented in the 
form of water electrolysis, is used because of its low power consumption, 
small physical size, minimal heat generation, simple construction, and 
large driving force (24–27). These features represent important advan-
tages over battery-powered thermomechanical micropumps reported 
in optofluidic devices designed for use in the brain (10). The specific 
layout includes a pumping chamber (radius, 1.2 mm; height, 1 mm) 
filled with an aqueous solution of potassium hydroxide (KOH; 50 mM) 
with an interdigitated electrode (Au/Cu: thickness, 200 nm/ 18 m; 
width, ~50 m; space, ~50 m) at its base (fig. S2) and an overlying 
reservoir filled with a drug, where a flexible membrane separates the 
chamber from the reservoir (Fig. 2, A and B). The gold coating pre-
vents corrosion of the copper electrodes. The flexible membrane consists 
of a thin film of polystyrene-block-polybutadiene- block-polystyrene 
(SBS; ~150 m), chosen because of its favorable mechanical proper-
ties and effective barrier characteristics (fig. S3 and table S1). Thin 
membranes of metal/Al2O3 (thickness, ~425 nm) seal the outlet 
ports of the reservoirs to prevent leakage or evaporation of drugs 
before infusion (Fig. 1E). An opening on the sidewall of each reser-
voir allows for replenishment of drugs, thereby enabling multiple cy-
cles of use (Fig. 1E). Removable layers of silicone elastomer (Kwik-Sil) 
seal the ports after filling.
Each reservoir connects to a microfluidic channel that terminates 
at an outlet integrated into the cuff (Fig. 1, D and E). The micropump 
chamber and reservoir are both milled from a block of cyclic olefin 
polymer (COP; thickness, 1 mm), selected for its low water absorp-
tion (<0.01%); resistance to hydrolysis, acids, alkalis, and polar sol-
vents; and efficiency as a moisture barrier (water vapor permeability, 
0.023 g·mm/m2·day) (10, 28). At 37°C, the rates of fluid loss due to 
diffusion into the COP are minimal, which is critical for chronic, 
long-term studies (Fig. 2C). Voltage applied to the interdigitated elec-
trodes in the pumping chamber initiates electrolysis via the reaction 
2H2O (liquid) → O2 (gas) + 2H2 (g) (24, 26). An electrolyte solution of 
50 mM KOH provides sufficient conductivity. The volume expan-
sion associated with the production of hydrogen and oxygen mechan-
ically deforms the flexible membrane (Fig. 2, A, B, and D, and movie S1). 
This deformation drives the flow of drug from the reservoir, through 
the microfluidic channel, and out of the corresponding outlet at 
the cuff (Fig. 2B and movie S2).
The pressure increases with time after activation of the micropump, 
as the generated gases accumulate in the sealed micropump chamber. 
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Under typical operating conditions (applied current, 0.3 mA), the 
pressure reaches ~108 kPa at the state of maximum deformation 
of the membrane, as the drug is completely expelled from the reservoir 
(1.5 l; fig. S4). The pressure inside the micropump chamber is mostly 
cancelled by deformation of the membrane, resulting in a much lower 
pressure (~7 kPa) in the drug reservoir (fig. S4). The bottom polyimide 
(PI) substrate barely deforms during this process as it is much stiffer 
(2.5 GPa) than the soft membrane (~13 MPa). Some of the pressure 
is released by transport of gases, primarily hydrogen, through the 
membrane. The remaining pressure remains in the micropump 
chamber until refilling. This pressure can be released by peeling off 
the removable layers of silicone elastomer (Kwik-Sil). Although a 
small amount of oxygen or hydrogen may pass through the SBS 
flexible membrane, their influence on the drugs is minimal (29).
The wireless powering system generates ~15 mW from a ~1-cm- 
diameter receiver coil (19), which is more than sufficient for full fluid 
delivery and -ILED illumination (Fig. 2E). The ultralow power 
consumption of electrochemical micropumps (Fig. 2E), compared with 
the battery-powered thermomechanical micropumps (10), enables 
wireless, battery-free operation, allowing the platform to operate 
with a much smaller size and weight than available alternatives. The 
removal of a battery component decreases overall device size, per-
mitting full implantation under the skin. The wireless powering sys-
tem eliminates any concern about operational longevity. While batteries 
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can provide robust power supplies, the constraints imposed to keep 
them small result in short life spans, making them difficult to use 
for extended behavioral experiments. 
Experimental evidence indicates that ~90% of the reservoir vol-
ume is delivered through the outlet at the cuff (Fig. 2F). At a voltage 
of ~3 V, a device with channel cross-sectional dimensions of 60 m 
by 60 m has a flow rate of ~1.5 l/min (Fig. 2G), without any 
measurable heating (Fig. 2H), which is an substantial advantage 
over previous technology, as heating can be detrimental to drug sta-
bility and efficacy (10). The flow rate is tuned by the applied voltage 
and by engineering the geometries of the reservoirs and channels. 
The pumping mechanisms, electrode designs, and refilling ports 
allow for reuse of the microfluidic system (fig. S5). In this pro-
cess, the electrolyte solution (50 mM KOH in water) and drugs 
can be loaded with syringes into the micropump chamber and 
drug reservoir, respectively, through the filling ports (fig. S5A) that 
are subsequently sealed. Figure S5B shows a system loaded before 
implantation and extracted after drug delivery in vivo.
Design and material properties of the soft neural cuff
The cuff interface consists of an elastomeric polymer [poly(di-
methylsiloxane), PDMS] that is thin (~200 m), mechanically soft, 
and flexible (modulus, ~3 MPa). The cuff is designed to minimize 
its effects on overall nerve health by using comparable mechanical 
properties with peripheral nerve tissue (mouse sciatic nerve modulus, 
~7 MPa) (30). Microfluidic channels and a -ILED (on a narrow, 
thin strip of PI with copper interconnect traces) embedded in the 
PDMS support the pharmacologic and optogenetic functionality of 
the system (Fig. 1, C to E). The serpentine shape of the PI filament 
that connects the cuff to the base station (“electrical interconnect”) 
provides mechanical stretch (~15 to 20%) to accommodate natural 
body movements (fig. S6, A and B). The stress-strain response of the 
optofluidic probe (integrated electrical interconnect, microfluidic 
channels, and cuff), evaluated by dynamic mechanical analysis, 
indicates an effective modulus of ~25 MPa (fig. S6C), higher than 
that of the cuff itself. Operation of the -ILEDs elevates the tem-
perature of the nerve only slightly (maximum increase of 0.85°C 
with constant illumination over 5 min), below thresholds for damage 
(fig. S7) (31).
The cuff is designed to form a cylindrical shape that wraps 
around the nerve (Fig. 1E). This geometry results from bonding two 
flat, thin strips of PDMS by corona treatment, one of which is in a 
state of prestrain (fig. S8, A to D). Releasing this prestrain yields a 
cylindrical shape with a radius that decreases with increasing 
prestrain, . The critical value cr required to form a cuff with inner 
radius Rnerve is shown in fig. S9A. In practice, the value of  is typically 
larger than cr such that the cuff has a radius somewhat smaller than 
Rnerve, leading to a modest contact pressure with the nerve to hold 
the cuff in place (fig. S9B). Results of analytical modeling indicate 
that the average contact pressure can be controlled to values below 
7 kPa, a threshold for damage to the sciatic nerve in mice (30), by 
use of a prestrain less than 38%. Experiments reported here involve 
prestrains of 30% (fig. S9C).
Effects of the optofluidic system on nerve health 
and function
The full optofluidic system was chronically implanted in mice to 
determine its effects on nerve health and function. In a single surgical 
procedure, the base station was secured over the thoracic curve of 
the vertebral column using two sutures through integrated eyelets 
to the underlying muscle. The cuff was then wrapped around the 
sciatic nerve, and the flap was fastened to the cuff lead (Fig. 3, A to C). 
One week after implantation, mice with the implant do not exhibit 
any behavioral indications of nerve damage compared to animals 
with a sham surgery, as measured through analysis of gait properties 
and locomotor coordination (Fig. 3, D to G; n = 9 sham; n = 10 device 
implantation). Two weeks after implantation, the cuff remains in its 
original position, with no signs of degradation in functionality 
(Fig. 3C and fig. S10, A and B; n = 10 device implantation). By 
comparison, a polyethylene (PE) tubing cuff results in clear deficits 
in coordination and changes gait parameters of the ipsilateral limb 
(Fig. 3, D to G; n = 8 to 10 PE cuffs). Compared to the optofluidic 
cuff system, the PE cuff has a relatively high modulus (~0.25 GPa) 
(32–34), and the inability of the PE cuff to conform to the curvature 
and motions of the soft tissues results in injury to the nerve (35). 
Mice with an implanted PE cuff (fig. S10C) also show a significant 
increase in immune cell infiltration in the sciatic nerve compared to 
either the optofluidic cuff system or sham animals (Fig. 3, H and I; 
n = 3 in each group).
In vivo demonstration of the optogenetic and microfluidic 
capabilities of the optofluidic system
Two different animal experiments illustrate the capabilities of this 
system. The first demonstrates the -ILED functionality in vivo and 
its ability to activate within a specific region of the experimental arena. 
Here, we used mice that express channelrhodopsin2 (ChR2), an excit-
atory opsin activated by blue light, in nociceptors (TRPV1-ChR2 
mice; see Materials and Methods). Optical stimulation (470 nm; blue 
light) of these neurons results in aversive behavior (18). One week 
after implantation, unilateral sciatic nerve stimulation with blue light 
at 1 Hz (pulse width, 10 ms), but not at 10 Hz, induces significant 
aversion to the stimulation chamber in TRPV1-ChR2 mice com-
pared to wild-type mice (Fig. 4, A to C; n = 10 wild type; n = 9 
TRPV1-ChR2).
The second set of experiments demonstrates both temporally 
defined fluid delivery to the sciatic nerve in vivo and the ability to 
deliver multiple drugs to the same animal without handling the ani-
mal between treatments. Here, two reservoirs (each with volumes of 
1.5 l) of the system contain saline and the other two contain 
bupivacaine (40 mg/ml), a nonspecific voltage-gated sodium channel 
blocker and local anesthetic. Five days after implantation, we as-
sessed thermal paw withdrawal thresholds at baseline, after saline, 
and after bupivacaine delivery (Fig. 4D). Delivery of bupivacaine 
significantly increases withdrawal latency compared to both base-
line and saline, indicating a decreased thermal sensitivity and 
induction of a sciatic nerve block, with no other indications of sys-
temic effects (Fig.  4E; n  =  6  in baseline and saline; n  =  5  in 
bupivacaine).
DISCUSSION
The wireless, battery-free, soft, fully implantable optofluidic cuff 
system reported here allows for long-term modulation of peripheral 
nerve activity via operation of a microfluidic system for localized 
drug delivery and a cointegrated -ILED for optogenetic stimulation. 
Critically, the system’s soft cuff interface does not damage the associated 
peripheral nerve and permits targeted delivery of light, as opposed 
to broad illumination (20, 21), in a manner that restricts activation 
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of optogenetic channels to a specific nerve. The ultralow-power, 
miniaturized electrochemical micropump system–driven microfluidic 
functionality bypasses limitations with traditional fluid delivery 
technologies by delivering time-locked pharmacological agents to 
specific nerves without the need to handle, inject, tether, restrain, or 
anesthetize the animals. In addition, because the system does not 
rely on batteries, it weighs substantially less than alternatives (10) 
and can be used in long-term experiments. Furthermore, by using 
NFC powering and communication protocols, the set-up costs and 
required expertise are markedly less than high-frequency alternatives 
(18, 36), allowing for high-throughput experiments with lower 
operation costs.
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Fig. 3. Implantation of the battery-free optofluidic nerve cuff system and its impact on animal behavior and nerve health. (A) Detailed illustration of the optofluidic 
nerve cuff system and cuff interface with the mouse sciatic nerve. (B) Demonstration of both optical stimulation and fluid delivery to the sciatic nerve. Scale bar, 2 mm. 
(C) Mouse chronically implanted with the wirelessly powered optofluidic nerve cuff system. (D) Characterization of effects of device implantation on rotarod performance 
compared to PE cuff and sham surgery [n = 9 to 10; ***P < 0.001 PE cuff versus sham and device, two-way analysis of variance (ANOVA)]. Mouse gait parameters including 
maximum contact mean intensity (E), swing time (F), and print area (G) are significantly impaired after PE cuff implantation but not after optofluidic cuff implantation 
compared to sham surgery (n = 8 to 10; ***P < 0.001, **P < 0.01, and *P < 0.05, one-way ANOVA with Tukey’s multiple comparison). Representative hematoxylin and eosin 
images (H) and quantification of infiltrating immune cells (I) from the sciatic nerve comparing sham, device, and PE cuff after 2 weeks (w) of implantation demonstrating 
an absence of infiltrating immune cells in sciatic nerves of mice implanted with the device compared to PE cuff implantation. Scale bars, 25 m. n = 3; ***P < 0.001, one-way 
ANOVA with Tukey’s multiple comparison. AU, arbitrary units.
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The capability for independent infusion of multiple drugs allows 
testing of several drugs in a single animal. For example, vehicle, agonist 
alone, antagonist alone, and an antagonist and agonist combination 
can be delivered independently to a single, awake, and behaving animal. 
In addition, the same drug can be tested before and after an experi-
mental manipulation. This mode of operation not only reduces the 
number of animals needed for any given experiment but also ex-
ploits each animal as its own control, as demonstrated here, to re-
duce experimental variability.
This same level of independent control over separate reservoirs 
and micropumps permits drugs to be simultaneously delivered to the 
nerve surface for time-controlled chemical reactions, of potential 
interest in combination therapies. In addition, dual optical and 
pharmacological operation enable studies that use optically activated 
drugs (10, 36, 37) and single-step optogenetics (38). One limitation of 
fully implantable drug delivery systems is compound stability at body 
temperature over extended periods of time. The stability of various 
compounds can be improved by careful testing of different delivery ve-
hicles and sterilization. Future technology could help improve these 
conditions by mixing lyophilized compounds on demand or alter-
ing the internal temperature of the drug reservoir.
Other systems that provide wireless drug delivery with or without 
light delivery, such as battery-powered, head-mounted platforms 
for studies of the brain (10), are not easily adaptable for peripheral 
use. The size and bulk of these platforms prevent them from be-
ing fully implanted and are not well suited for interfacing with 
the PNS. Alternatives include wireless power transfer using RF operation 
in the UHF (ultrahigh-frequency, 300–3,000 MHz) band (36), but 
this system has disadvantages including tissue absorption, reflec-
tions, and sensitivity to orientation and polarization (39, 40). Other 
platforms use commercially available miniaturized pumps (3), battery 
power, and stainless steel needles, but they cannot be used readily 
in small animals because of their bulky size.
The system introduced here eliminates many of the substantial 
disadvantages inherent in previously described technologies. We 
demonstrate the ability of this platform to positively (optogenetic 
stimulation) and negatively (bupivacaine delivery) modulate sciatic 
nerve activity in freely moving animals. In addition, these devices 
have the potential to target much smaller nerve branches to provide 
more specific stimulation, such as the pelvic nerve to modulate 
bladder function (41). Furthermore, the core ideas and the supporting 
technology platforms can be adapted to other non-neuronal or central 
nervous system structures. For example, the cuff could easily be 
enlarged to accommodate hollow organs such as the colon, trachea, 
or esophagus. In addition, more intricate interface architectures could 
be tailored to target organs such as the heart, liver, or pancreas, 
each with radically different shapes. This interface could also be adapted 
into a small flexible probe for placement in the intrathecal space 
(18), to manipulate spinal cord neurons, or designed on a rigid 
structure for stereotaxic implantation into different brain regions 
(10). Overall, the system introduced here improves the tool set 
available for advanced manipulation of peripheral nerves in awake, 
freely moving animals to further characterize and develop func-
tional maps of the PNS.
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MATERIALS AND METHODS
Fabrication of the soft nerve cuff
As described in the main text, formation of the cuff relies on effects 
in controlled mechanical buckling. The fabrication began with 
spin-coating a precursor to PDMS (10:1 prepolymer/curing agent; 
800 rpm for 60 s; Sylgard 184, Dow Corning) on a thin plate (1.5 mm) 
of polycarbonate (PC) followed by thermal curing. Corona treat-
ment enabled bonding of a strip of PDMS (thickness, 100 m; width, 
~2 mm; length, 1 cm) formed in this way to another piece (thick-
ness, 100 m; width, ~1.5 mm; length, 3 cm) while under a state of 
prestrain. Releasing the prestrain led to the formation of a cylindri-
cal shape.
Fabrication of the microfluidic probe
The soft microfluidic probe consists of two layers, a molded micro-
channel layer and a capping layer, bonded by corona treatment. The 
fabrication process began with formation of a mold in the geometry 
of the microfluidic channels by photolithography and deep reactive 
ion etching (STS Pegasus ICP-DRIE; SPTS Technologies, Newport, 
UK) on the surface of a silicon wafer. A glass slide (length, 75 mm; 
width, 50 mm; thickness, 1 mm; Corning Microscope Slides, Corning, NY, 
USA) treated with a Pt inhibitor, a solution of 5% [3-(2-aminoethylamino)
propyl]trimethoxysilane (Sigma-Aldrich, St. Louis, MO, USA), and 
95% methanol by weight, facilitated the release of a layer of PDMS 
(elastomer/curing agent ratio, 10:1; Sylgard 184, Dow Corning) cast 
between the glass slide and the patterned silicon wafer. A layer of 
Scotch tape served as a spacer at the boundary of the slide to define 
the thickness of the PDMS. A thin layer (~60 nm) of polymethyl 
methacrylate (PMMA A2; MicroChem, MA, USA) spin-cast on the 
silicon mold served to prevent adhesion between the silicon mold 
and the PDMS. Curing in an oven at 70°C for 45 min and then 
carefully releasing the glass slide with the patterned PDMS layer 
from the silicon mold completed the fabrication of the thin micro-
fluidic channel layer (thickness, ~100 m). A capping layer of 
PDMS (thickness, ~100 m) was prepared by spin-casting (elastomer/
curing agent ratio, 10:1; Sylgard 184, Dow Corning) on a PC sub-
strate and baking at 70°C for 45 min. Bonding this cover layer to the 
microfluidic channel after activating the surfaces with a laboratory 
corona treater (Electro-Technic Products) yielded a microfluid-
ic probe. The PC sheet was then peeled away, and the probes were 
released from the glass slide with a razor blade.
Fabrication of the -ILED probe
Fabrication began with a clean glass slide (length, 75 mm; width, 
50 mm; thickness, 1 mm; Corning Microscope Slides, Corning, NY, 
USA) coated with PDMS formed by spin-casting at 1000 rpm for 60 s 
followed by curing at 70°C for 1 hour. A sheet of copper-coated PI 
(9 m/12 m, copper/PI) was then laminated on top. Photolithography 
(AZ 5214, AZ Electronic Materials) and wet etching defined a pattern 
of copper traces. A 12-m-thick layer of PI (PI-2545, HD MicroSystems), 
formed by spin-casting and curing at 250°C for 2 hours, served as 
an encapsulation layer and a means to locate the copper near the 
position of the neutral mechanical plane. Photolithography and 
reactive ion etching then defined the PI/metal/PI sheet into serpentine- 
shaped structures. A -ILED (TR2227, Cree Inc.) was placed onto 
the exposed pads with a small amount of solder paste (Indalloy 290, 
97.0In/3.0Ag, Indium Corporation). The resulting probe was released 
from the glass substrate by laser cutting of the patterned PI/metal/
PI sheet (ProtoLaser U4, LPKF, Germany).
Finite element analysis of the optofluidic probe
Three-dimensional finite element analysis was performed using 
commercial software Abaqus to study the deformation and strain in 
the serpentine wire under stretching. Solid elements (Abaqus element 
type C3D8R) were used for the 300-m-thick PDMS, and shell 
elements were used for the serpentine-shaped PI/metal/PI layers. 
The maximum strain in the metal layer is well below tensile limit, 
1% under 15% stretch of the optofluidic probe.
Fabrication of base station
A flexible sheet of copper-clad PI (Cu/PI/Cu, 18 m/75 m/18 m; 
DuPont, Pyralux) served as the substrate. The transmission coil and 
interdigitated electrodes were defined on both sides with an ultraviolet 
laser cutting tool (ProtoLaser U4, LPKF, Germany). Holes (diameter, 
50 m) were drilled through the substrate using the same tool. Pulsed 
direct-current electroplating of copper filled the sidewall of these 
holes to define electrical connections between the top and bottom 
layers. The interdigitated electrodes were coated with gold (200 nm) by 
electroless plating to prevent oxidation of the copper in the presence of 
KOH solution. The critical electronic components, including a capacitor 
(02016D225MAT2A, AVX Corporation), a rectifier (SMS7621-040LF, 
Skyworks Solutions Inc.), an indicator (APG0603SURC-TT, Kingbright 
Company LLC), and a microcontroller (ATTINY84A-MU, Microchip 
Technology), were then placed and attached using reflow soldering 
with a low- temperature solder (Indium Corporation). The -ILED 
probe was aligned and soldered onto the electronic base station using 
a low- temperature solder. A layer of epoxy (thickness, ~500 m; 
Loctite Epoxy Marine) applied as an overcoat prevented delamina-
tion of the electronic components. The final step of the fabrication 
involved application of a uniform encapsulation bilayer of parylene 
(14 m; Specialty Coating Systems) and PDMS (~200 m, dip coating).
Preparation of the metal/Al2O3 membrane
Fabrication began with a PI film (thickness, 12.5 m) with a layer of Cu/Au 
(thickness, 250 nm/150 nm) formed by electron beam evaporation 
(e-beam evaporator, AJA International). The metal-coated PI film 
was then laminated on a clean glass slide (length, 75 mm; width, 50 mm; 
thickness, 1 mm) (Corning Microscope Slides, Corning, NY, USA), 
with a coating of PDMS formed by spin-coating (1000 rpm for 60 s) 
followed by curing at 70°C for 1 hour. Photolithography (AZ 4620, 
AZ Electronic Materials) and reactive ion etching defined a metal 
membrane (radius, ~1.2 mm; thickness, 400 nm) supported by a PI 
film (fig. S11). Last, atomic layer deposition formed a layer of aluminum 
oxide (Al2O3; thickness, 25 nm) on the metal membrane.
Preparation of flexible membrane
The fabrication began with dissolution of SBS (Sigma-Aldrich, MO, 
USA) in toluene with sonication. The SBS solution (4 g/40 ml) was 
then cast on a silicon wafer pretreated with mold release spray (Ease 
Release 200, Mann Release Technologies Inc., PA, USA) for 5 min 
and then annealed at 60°C (~3 hours) and then at 95°C (overnight). 
A bilayer of Ti/SiO2 (5 nm/20 nm) deposited by sputtering (AJA 
International) rendered the surface of the SBS film hydrophilic.
Fabrication of the micropump chamber and pharmacological 
agent reservoir
Fabrication of the micropump chamber and drug reservoir involved 
milling a block of COP (thickness, 1 mm). Deposition of a bilayer of 
Ti/SiO2 (5 nm/50 nm) by sputtering (AJA International) onto the 
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inner surface of the reservoir rendered it hydrophilic to facilitate 
filling with aqueous solutions.
Assembly of the device
Schematic illustrations of the assembly of the device are shown in 
fig. S12. Cylindrical micropump chambers patterned in the COP 
were aligned to the interdigitated electrodes and bonded with a com-
mercially available sealant (3M marine adhesive sealant fast cure 5200) 
to prevent evaporation or leakage of electrolyte. The flexible mem-
brane of SBS (~150 m) was attached on the bottom of the reservoirs 
with a pressure- sensitive adhesive (Adhesives Research Inc., EL-8932EE). 
The reservoirs in the COP were aligned on the micropump chamber 
and bonded using the same sealant (3M marine adhesive sealant fast 
cure 5200). The metal/Al2O3 membrane (thickness, 400 nm/25 nm; 
radius, ~1.2 mm) was mounted on the four outlets of the reservoirs 
using the same double-sided pressure-sensitive adhesive to seal the 
device and prevent fluid evaporation. The inlets of the microfluidic 
probe were aligned and bonded to the outlet ports of the reservoirs 
using the same double- sided pressure-sensitive adhesive. The -ILED 
probe and microfluidic channels were aligned and bonded with a sil-
icone adhesive (Kwik-Sil, World Precision Instruments). Last, a soft 
PDMS cuff was bonded with the optofluidic probe using the same 
silicone adhesive.
Animal testing
All procedures were approved by the Animal Care and Use Committee 
of Washington University and were in strict accordance with the 
U.S. National Institutes of Health (NIH) Guide for the Care and Use 
of Laboratory Animals. Adult male mice (8 to 14 weeks of age) used 
in experiments were housed in the Washington University School 
of Medicine animal facilities on a 12-hour light/dark cycle with 
access ad libitum to food and water.
For relevant optogenetic experiments, mice were generated with 
conditional expression of ChR2 in nociceptive sensory neurons by 
crossing heterozygous TRPV1-Cre mice [provided by M. Hoon 
(National Institute of Dental and Craniofacial Research)] (42) with 
homozygous Ai32 mice harboring ChR2 in the Rosa locus (stock 
no. 012569, the Jackson laboratory) (43). For the purposes of this 
study, we refer to these mice as “TRPV1-ChR2.” These mice are 
further characterized in the work of Park et al. (18). Heterozygous 
Ai32 mice (Cre-negative mice) were used as controls. All other 
experiments were performed using C57BL/6J mice bred in-house or 
obtained from the Jackson laboratory.
Procedures for implantation
Mice were anesthetized with vaporized isoflurane, and their eyes were 
covered with Altalube ointment (Altaire Pharmaceuticals, Riverhead, 
NY, USA) to prevent corneal drying. A small skin incision was made 
over the greater trochanter of the femur on the left flank of the animals. 
The fascia connecting the biceps femoris and the gluteus maximus 
was blunt-dissected apart to open a plane between the muscles, in 
which the sciatic nerve was clearly accessible. A skin incision was made 
on the thoracic curve of the vertebral column and a subcutaneous 
pocket generated by blunt dissection. The body of the device was 
inserted under the skin into the subcutaneous pocket and sutured 
in place using an Ethicon 4-0 vicryl suture (Cornelia, GA, USA) to 
the underlying muscle through eyelets on each side of the device. 
For sham surgeries, the sciatic nerve was exposed and isolated, but 
no device was implanted. To test effects of higher modulus materials, a 
2-mm section of a split PE-20 PE tubing [inside diameter, 0.38 mm;outer 
diameter, 1.09 mm; ~0.25 GPa (32–34)] was placed around the nerve 
for comparison to the optofluidic cuff (35).
Hematoxylin and eosin histological evaluations
Two or 10 weeks after cuff implantation, mice were deeply anesthe-
tized with a ketamine, xylazine, and acepromazine cocktail and then 
transcardially perfused with cold 4% paraformaldehyde in phosphate- 
buffered saline. Sciatic nerves were dissected from mice implanted 
with the device or PE cuff or from sham mice and post-fixed in 4% 
paraformaldehyde overnight. Nerves were embedded in paraffin 
and longitudinal sections were cut at 6 m. Slides were stained 
with a standard hematoxylin and eosin protocol (18, 44). Repre-
sentative 40× images taken from the center of the nerve were ob-
tained using a Leica DM6 B microscope, and infiltrating immune 
cells were counted (18). Three mice were analyzed for each condition, 
and three nerve sections were evaluated from each mouse. Two images 
were obtained from each nerve section, and the average number of 
immune cells present in the six images was calculated. The investigator 
performing the analysis was blinded to the experimental condition.
Behavioral analyses
For behavioral studies, a priori power analyses were performed to 
estimate necessary sample sizes. The experimenters were blind to 
genotype and treatment (device implantation versus sham versus PE 
cuff positive controls) for all analyses. Animals from each genotype 
were randomly selected for treatment.
Rotarod test
Mice were assessed for gross motor function using an accelerating 
Rotarod (Ugo Basile). Mice were trained until they were able to 
remain on the Rotarod (4 rpm) for 120 s. One hour after training, 
five consecutive trials were performed on an accelerating Rotarod 
with 5 min between trials. Latency to fall was measured as the apparatus 
accelerated from 4 to 40 rpm over 5 min.
Gait analysis
Gait analysis was performed using the automated gait analysis 
hardware (CatWalk XT 10.5, Noldus) with the standard mouse 
calibration (camera gain, green light intensity, run duration, and 
run maximum variation). All animals were acclimatized to the CatWalk 
system twice for 15 min, 1 day before testing. Mice were tested 2 weeks 
after surgical implantation of the optofluidic device/PE cuff or sham 
surgery). Four compliant runs were required for each mouse, and 
parameters were averaged. Runs were deemed compliant if the run 
duration was between 0.5 and 5 s (through the camera field of view) 
and the maximum variation in run speed was less than 60% (45). 
These criteria were previously determined to be optimal for eliminating 
runs where mice did not continue to move through the field of view 
(45). Any runs that did not meet these criteria were characterized by 
the software as noncompliant and removed from further analysis. 
Swing time is a measure of how long the paw was off the ground. 
Print area measures the total area (in cm2) that the complete print covers 
during a step. Mean contact intensity is an indirect measure of paw 
pressure on the ground during the point of maximum contact (0 to 255).
Real-time place aversion experiments
Place aversion was tested in a custom-designed plexiglass chamber 
with a layer of corn cob bedding (18, 21). Each arm of the two-arm 
 o
n
 Septem
ber 4, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Zhang et al., Sci. Adv. 2019; 5 : eaaw5296     5 July 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
10 of 11
V-maze was 10 cm wide, 33 cm long, and 10 cm high with a neutral 
area between the two arms. The signal was generated in one arm 
only by tethering the designated arm with a double loop antenna. 
The signal was attenuated to allow for complete local field coverage 
and precise control of -ILED device power within the designated 
arm. Each mouse was placed in the neutral area of the chamber, and 
activity was continuously recorded using a video camera for a period 
of 20 min. “Time in chamber” and heat maps were generated for 
data using EthoVision software (Noldus, Leesburg, VA, USA). The 
-ILED device was instantaneously and automatically switched to 
the “ON” state each time the mouse entered into the double-loop 
antenna–equipped arm. Similarly, the -ILED device was automatically 
switched to the “OFF” state each time the mouse exited the antenna- 
equipped arm. Software and hardware for generating the signal were 
from NeuroLux Inc. (Champaign, IL, USA).
Hargreaves test
Animals were acclimated on a glass plate held at 30°C (model 390 
series 8, IITC Life Science Inc.). A radiant heat source was applied 
to the hindpaw, and latency to paw withdrawal was recorded (46). 
Three trials were conducted on each paw, with at least 5 min between 
testing the opposite paw and at least 10 min between testing the 
same paw. To avoid tissue damage, a cutoff latency of 20 s was set. Values 
from each paw were averaged to determine withdrawal latency.
Statistical analysis
All experiments were performed on adult male mice (8 to 14 weeks 
of age) and were randomly assigned to control or experimental 
groups and device implantation. Sample sizes were determined 
from preliminary experiments using the software G*Power for the 
appropriate type of statistical comparison. For place preference and 
thermal sensitivity assays, data were excluded from animals where the 
device was obviously damaged. All data were collected in a nonbiased 
manner, and the experimenter was blinded to treatment for histological 
analysis and to animal genotype for the place preference assay. One-way 
and two-way analyses of variance (ANOVAs) were performed as 
appropriate. P values <0.05 were considered statistically significant. 
All graphs are represented as means ± SEM. Further statistical 
details can be found in tables S3 and S4.
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